Unicancer
Suzette Delaloge is a distinguished medical professional currently serving as the Director of the Cancer Interception Programme at Gustave Roussy, a position held since 1999, emphasizing personalized prevention and early detection of cancer. In addition, Suzette Delaloge holds roles as an Assistant Professor in Medical Oncology and heads the Breast Cancer Group at Unicancer, while chairing significant initiatives such as the MyPeBS European consortium, which examines personalized screening strategies for breast cancer. As an active contributor to the scientific community, Suzette Delaloge serves as the Editor of the Breast Cancer section for the European Journal of Cancer and participates in various leadership positions within ESMO, including Deputy Chair of the Real World Data and Digital Health Working Group and Chair of the ESMO Breast Conference 2022-24. Educational qualifications include a Medical degree and multiple Master's degrees in Oncology, Cancer Biology, and Human/Medical Genetics from prestigious institutions in France.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries